应用Amplatzer封堵器关闭32例膜部室间隔缺损

目的　观察Amplatzer膜部室间隔缺损封堵器关闭膜部室间隔缺损的临床疗效及安全性。方法　经超声心动图及临床表现诊断为膜部室间隔缺损患者 ,如有临床症状但没有右向左分流 ,且膜部室间隔缺损的局部解剖结构满足以下条件 :(1)膜部室间隔缺损离主动脉瓣至少 1mm ,离三尖瓣隔瓣至少 3mm ;(2 )室间隔缺损的最窄直径小于 14mm ;(3)伴膜部室间隔瘤形成时 ,瘤体未影响右心室流出道 ;(4 )外科手术关闭膜部室间隔缺损后遗留的室间隔缺损 ,且对心脏的血流动力学有影响。在局部或全身麻醉下对患者行经导管Amplatzer双面伞膜部室间隔缺损的关闭治疗 ,手术中连续经胸或经食管超声心动图和X线监测。术后随访 3个月。结果　自 2 0 0 2年 6月至 2 0 0 3年 3月共有 32例患者行经导管Amplatzer双面伞膜部室间隔缺损的关闭治疗 ,其中男 17例 ,女 15例。超声测定膜部室间隔缺损直径为 3～ 8mm(平均 5 1mm) ,左心室造影测定膜部室间隔缺损的直径为 3～ 8mm(平均 4 4mm) ,所选Amplatzer膜部室间隔缺损封堵器直径为 4～ 12mm(平均 7 6mm)。堵闭操作技术成功率为 10 0 %。超声心动图示术后即刻残余分流为 11 5 % (少量分流 3 8% ,微量 7 7% ) ,2 4h后残余分流为 7 7% (为微量 ) ,3个月后有 3 8%的微量分流。手术中出现一过性     

Percutaneous device closure of congenital and iatrogenic ventricular septal defects in adult patients

Objectives : We report our 10‐year experience with percutaneous closure of adult congenital and acquired (non‐post‐infarct) ventricular septal defects (VSDs) using different types of Amplatzer occluder devices. Background : Adult congenital and acquired VSDs may produce significant morbidity and mortality. Furthermore, such VSDs pose a significant surgical challenge. Methods : Between February 2000 and August 2009, data were retrospectively reviewed from 28 patients who underwent 29 procedures for percutaneous device closure of hemodynamically significant VSDs. Seventeen had unrepaired congenital VSDs, 10 had post‐operative VSDs (5 with residual patch‐margin defects, 4 post‐aortic valve replacement, 1 post‐myomectomy), and one had an acquired traumatic VSD. Indications for closure included : symptoms related to significant shunt (dyspnea on exertion); unexplained deterioration of LV function, and/or LV dilation; recurrent endocarditis, and pulmonary hypertension. Outcome parameters were procedural success, procedure‐related complications, evidence of residual shunt by echocardiography, and improvement in the signs/symptoms for which the procedure was performed. The mean follow‐up interval was 68 months. Results : Of the 28 patients studied, a single VSD was present in 26 patients, while one patient had two defects, and one patient had one defect on the LV side with three openings at the RV side. The median size of the defects by echocardiography was 6 mm. A device was successfully implanted in 28 of 29 (97%) procedures and 28 of 28 (100%) patients. Procedure‐related complications occurred in two cases : one involving an access site hematoma not requiring transfusion as well as nonsustained ventricular tachycardia that resolved spontaneously and the other involving acute mitral regurgitation due to inadvertent trapping of the anterior mitral valve leaflet between the left ventricular disk and the septum that was resolved by recapturing of the disk. There was immediate complete closure in 20 patients (71%). In six cases there was trivial residual shunt and in two patients the residual shunt was mild. At the latest follow‐up, four of the eight with a residual shunt had no shunt and in the remaining four the residual shunt was trivial. Among symptomatic patients 18 (64%), there was marked improvement in symptoms and for those patients 17 (61%) for whom the procedure was performed to address left ventricular enlargement, there was reduction or stabilization in LV size on serial echoes. Conclusions : Percutaneous closure of VSDs in the adult patient appears to be safe and effective. © 2010 Wiley‐Liss, Inc.     

Catheter therapy of Swiss cheese ventricular septal defects using the Amplatzer muscular VSD occluder.

The medical and surgical management of patients with multiple muscular ventricular septal defects (VSDs) is associated with morbidity and mortality. Three children with Swiss cheese VSDs were treated with transcatheter occlusion of their multiple defects using the Amplatzer muscular VSD occluder. Seventeen defects were closed in five catheterization procedures. One patient had three devices placed in two procedures, the second had five defects closed in one procedure, and the third had nine defects closed in two procedures. Two patients had previously been treated with pulmonary artery banding and required subsequent surgical band removal. There was immediate reduction in the left-to-right shunting and clinical improvement in all patients. Complications included the need for blood transfusion during the two longest procedures and tricuspid valve regurgitation in one. Transcatheter occlusion of multiple VSDs is an acceptable alternative or adjunct to surgical therapy for these complex patients.     

Transcatheter closure of perimembranous ventricular septal defects

Although effective, transcatheter closure of perimembranous ventricular septal defects (pmVSD) with the Amplatzer Membranous VSD Occluder (AGA Medical Corporation, MN) carries a substantial risk of complete heart block, prompting many to abandon this intervention. A newly designed Amplatzer device for pmVSD was modified, in part, to minimize this risk. After rigorous preclinical testing, we report the first human experience with the Amplatzer Membranous VSD Occluder 2 (AGA Medical Corporation) in two patients (a 5‐year old with a 12‐mm pmVSD and a 26‐year‐old male with a 8‐mm defect). Both procedures were successful, with no adverse events at 7 and 4 weeks of follow‐up, respectively. Herein, we discuss characteristics of the new device, potential advantages compared to the prior version, and main technical aspects related to the procedure. © 2013 Wiley Periodicals, Inc.     

应用Amplatzer封堵器治疗室间隔缺损及对心脏传导系统的影响

目的　探讨新型Amplatzer室间隔缺损封堵器治疗膜周部及肌部室间隔缺损 (VSD)的疗效和对心脏传导系统的影响。方法　 2 0 0 3- 0 7～ 2 0 0 4 - 0 4采用新型Amplatzer膜部及肌部VSD封堵器对 12例膜周部VSD和 2例肌部VSD患者进行封堵治疗。对心脏多普勒超声检查符合导管封堵条件病人术前常规进行心导管检查 ,测定血流动力学各项参数。在X线透视、食管或经胸超声的监测下建立股动静脉轨道 ,经右心系统释放封堵器。对 12例膜周部VSD病人在手术前、后进行心内电生理检查 ,测定房室传导时间 (AV间期 )和房室结不应期 ,观察封堵手术对心脏传导系统的影响。病人分别于术后 2周、1个月、3个月、6个月进行随访。结果　 14例患者 (男 8例 ,女 6例 )封堵器置入全部成功。术后即刻超声及造影均示完全封堵 12例 ,微量残余分流 2例 ,均在 1d内消失 ,总完全封堵率为 10 0 %。 12例膜周部VSD病人封堵后即刻AV间期有不同程度的延长 ,其中 3例术后AV间期 >2 0 0ms,1周后心电图检查 2例PR间期恢复正常。封堵前后房室结不应期无明显变化。未出现Ⅱ度以上房室传导阻滞和束支传导阻滞 ,无心肌受损表现 ,无其它严重并发症发生。结论　应用新型Amplatzer膜部和肌部VSD封堵器治疗膜周部和肌部VSD是安全有效的 ,近期效果良好 ,是导     

Transcatheter closure of postsurgical residual ventricular septal defects: Early and mid‐term results

Background: The incidence of residual ventricular septal defects (VSDs) after surgery is 5–25%. Redo surgery is associated with higher risks. Methods: Between January 2000 to December 2008, 170 patients underwent percutaneous VSD closure in our centre: 22(16M) of these had 23 closures for residual VSDs. Median age was 32.5 yrs (1.4–79). All patients had echocardiographic signs of left ventricle volume overload (Q_p/Q_s ≥ 1.5). Nine patients had previous VSD closure, 6 tetralogy of Fallot repair, and 7, other procedures. There were 15 muscular, 6 perimembranous and 2 apical VSDs. Results: Amplatzer VSD devices were used in all. Median VSD size was 8 mm (4.3–16). Median fluoroscopy time was 33 minutes (15–130). There were three adverse events: 1 ventricular fibrillation requiring DC cardioversion; 1 transient complete atrio‐ventricular block reverting to sinus rhythm at 24‐hours; one patient had transient atrial flutter during the procedure. All procedures were successful; no additional procedures were required. Trivial residual shunts were seen in 3 patients at follow‐up. There were no late events. One patient experienced arrhythmic death 5‐yrs after procedure. One patient was reoperated due to dehiscence of VSD patch 2‐yrs after the second successful percutaneous closure. Conclusions: Transcatheter closure of postsurgical residual VSD is safe and efficacious management option and obviates the need for further surgery and by‐pass. © 2009 Wiley‐Liss, Inc.     

Percutaneous closure of an iatrogenic ventricular septal defect following mechanical aortic valve replacement using the transseptal technique.

Iatrogenic ventricular septal defects (VSDs) following aortic valve replacement are relatively uncommon and are challenging to close percutaneously given their typical proximity to the prosthetic valve. We describe the successful percutaneous closure of an iatrogenic VSD in a patient with a recent mechanical AVR using the transseptal approach.     

Device closure of ventricular septal defects by hybrid procedures: A multicenter retrospective study

Objective : This study reports on the feasibility, efficacy, and outcome of hybrid procedures to close ventricular septal defects (VSD), reflecting the experience of 11 centers in Germany, Austria, and Switzerland. Background : Beating heart closure of VSD has attracted interest in small infants, complex anomalies and postinfarction scenarios where patients are at high risk during surgery. Perventricular or intraoperative device placement allows access to the lesions where percutaneous delivery is limited. Methods : Between December 2001 and April 2009, placement of Amplatzer septal occluders was attempted in 26 patients. The defects were located in the perimembranous (n = 5) and muscular septum (n = 21). In 20 patients, a perventricular approach was used, and, in six, the occluders were placed under direct visualization being part of a complex heart surgery. Results : In 23 of 26 procedures, device placement was successful (88.5%). The mean defect size was 7.8 mm (range, 3.5–20). The occluder types were perimembranous VSD occluder (n = 4), muscular VSD occluder (n = 20), postinfarct VSD occluder (n = 1), and ASD occluder (n = 1) with a ratio device/defect of 0.9–2.4 (median 1.15). Device removal was necessary in three due to arrhythmia, malpositioning, and additional defects. Pericardial effusion occurred once. In the remaining 22 patients, there were no procedure or device‐related complications. During mean follow up of 1.4 years (range, 1 day–3.9 years), a residual shunt that was more than trivial was observed in one patient out of 21 successful procedures. Conclusions : Perventricular and intraoperative device closure of VSD is as effective as a surgical patch and averts the increased morbidity of conventional surgical repair in a subgroup of high‐risk patients. © 2010 Wiley‐Liss, Inc.     

经导管应用Amplatzer封堵器关闭膜周部室间隔缺损

目的 :经导管应用Amplatzer封堵器关闭膜周部室间隔缺损 (perimembranousventricularseptaldefect,PMVSD) ,并对其疗效进行初步分析。方法 :18例室间隔缺损 (VSD)中男性 8例 ,女性 10例 ,平均年龄 7 6岁 ,平均体重 2 6 9kg。局麻下行右心导管检查 ,左室造影测量室缺大小 ,经VSD建立股动脉 股静脉轨道 ,封堵器沿传送装置送至左室 ,打开左侧伞并确认铂金标记 (MARK)位于 6点位 ,指向心尖 ,在室间隔右室侧打开右侧伞 ,经超声心动图和左室造影确认封堵器位置良好 ,无残余分流 ,无三尖瓣及主动脉瓣关闭不全后释放封堵器。结果 :18例VSD患者封堵手术均获成功。VSD平均大小 3 9mm ,所选封堵器平均大小 7 1mm ,放射线观察MARK均在 6点位置。封堵效果良好 ,术后 2 4h左室舒张末径明显缩小 ;术后 2 4h仅 2例有微量残余分流 ,无 1例出现主动脉瓣关闭不全 ,无其它严重并发症 ,平均住院3 5d。结论 :经导管应用Amplatzer封堵器关闭膜周部VSD封堵效果好 ,恢复快 ,免除开胸创伤及体外循环等高风险 ,值得进一步推广。     

Transcatheter closure of a posttraumatic ventricular septal defect with an Amplatzer occluder device.

Cardiac traumatization may lead to severe complications. Transcatheter closure of a postraumatic ventricular septal defect (VSD) was successfully done using an Amplatzer septal occluder in a man who had previously undergone surgery for myocardial fissure and mitral valve dysfunction. In selected cases, the percutaneous approach may be a valuable option to close muscular VSDs.     

Device closure of muscular ventricular septal defects in infants less than one year of age using the Amplatzer devices: feasibility and outcome.

OBJECTIVES: In this study, we evaluated the feasibility, safety, and outcome of device closure of muscular ventricular septal defects (mVSD) in infants less than 1 year of age using the Amplatzer devices. BACKGROUND: Closure of mVSDs continues to represent a surgical challenge with significant morbidity. Hence, device closure is becoming an attractive and reliable alternative. However, little is known about the feasibility of this procedure in small infants. METHODS: Between July 1999 and September 2006, device closure of mVSD was attempted in 20 infants ranging in age from 3 days to 12 months (median +/- SD; 4.6 +/- 3.8) and in weight from 3.2 to 8.9 kg (4.6 +/- 1.9) under TEE guidance by percutaneous or hybrid (perventricular) techniques. The size of the VSD as assessed by TEE ranged from 3 to 11 mm (6.0 +/- 2.2) and the Qp:Qs ratio ranged from 0.7 to 8.8 (2.8 +/- 2.3). RESULTS: The device was successfully placed in 19/20 infants and it ranged in size from 4 to 14 mm (8.0 +/- 2.6). It was percutaneously deployed in 11/19 and by the hybrid approach in 8/19. There were 30 devices placed in 19 infants with multiple devices placed in 5/19 infants. Fluoroscopy times ranged from 11 to 136 min (41 +/- 28) and procedure times ranged from 57 to 291 min (178 +/- 68). The success rate as defined by complete closure or a trivial shunt was 84% immediately and 100% at 1-year follow-up. Major complications occurred in 4/20 patients: wire perforation and hemopericardium (n = 1), device migration (n = 1), transient electromechanical dissociation (n = 1), and mediastinitis (n = 1). At a median follow-up of 3.8 years, all patients improved and had no hemodynamically significant VSDs. No major complications were encountered in patients with multiple devices. CONCLUSION: In infants less than 1 year of age, percutaneous and perventricular device closure of mVSDs is technically feasible and highly effective with low morbidity. Long term safety and efficacy needs to be assessed.     

应用新型Amplatzer封堵器治疗膜周部室间隔缺损的初步研究

目的　探讨新型Amplatzer室间隔缺损封堵器治疗膜周部室间隔缺损 (VSD)的可行性及近期疗效。方法　 2 0 0 2年 11月至 2 0 0 3年 7月采用新型Amplatzer膜部VSD封堵器对 2 6例 (男 11例 ,女 15例 )膜周部VSD(2 0例合并膜部瘤 )患者进行封堵治疗。患者年龄 3～ 4 0 (16 4± 10 7)岁 ,胸超声提示VSD的直径为 3～ 14 (4 7± 1 0 )mm。在透视及超声监测下通过建立股动静脉轨道、经右心系统释放封堵器 ,并分别于术后 2周、1个月、3个月、6个月进行随访。结果　 2 5例患者封堵器置入成功 ,技术成功率 96 %。术后即刻超声及造影均示完全封堵 2 0例 ,少量残余分流 2例 ,微量残余分流 3例 ,均在 1天至 3个月内消失 ,总完全封堵率为 10 0 %。术后出现完全性左束支传导阻滞 1例 ,但无心肌受损表现 ,余无其他严重并发症发生。 1例嵴内型VSD由于距主动脉瓣较近 ,封堵未成功。结论　应用新型Amplatzer膜部VSD封堵器治疗膜周部VSD是安全有效的 ,近期效果良好 ,但中、远期疗效尚需更大规模的临床观察     

Outcomes and alternative techniques for device closure of the large secundum atrial septal defect.

Outcomes of device closure of large and small secundum atrial septal defects (ASDs) as related to rim anatomy with the Amplatzer atrial septal occluder were compared. Rim adequacy (> or = 5mm) of the anterior, inferior, posterior, and superior rims was determined using transesophageal echocardiography. Balloon-stretched defect size defined patients into two groups: group 1, < or = 25 mm (n = 138); group 2, > 25 mm (n = 34). Rim deficiency (n = 62) was more frequent in group 2 compared to group 1 (50% vs. 33%; P = 0.07), especially inferior rim deficiency (35% vs. 2%; P = 0.005). Device deployment was successful in group 1 and group 2 (100% vs. 91%; P = 0.007). Unsuccessful deployment was associated with an ASD of > 25 mm (P = 0.007) and inferior rim deficiency (P = 0.001). At first follow-up (54 +/- 16 days), right ventricular systolic pressure had improved in both groups (P < 0.001). Closure of a large ASD associated with a lack of support in the inferior rim may warrant alternative strategies to position the device successfully.     

Transcatheter closure of post-myocardial infarction ventricular septal defect with Amplatzer septal occluder.

Rupture of the interventricular septum is an uncommon but often fatal complication of acute myocardial infarction. Transcatheter closure is an established method of treating selected congenital defects but clinical experience on transcatheter closure of postinfarction ventricular septal defects (VSDs) is minimal. We report a case of successful transcatheter closure of postinfarction VSD using the Amplatzer septal occluder.     

Immediate primary transcatheter closure of postinfarction ventricular septal defects

Aims: Immediate surgical repair of ventricular septal defect (VSD)complicating acute myocardial infarction is associated withhigh mortality. Percutaneous device closure appears to be safeand effective in patients treated for a residual shunt afterinitial surgical closure, as well as in patients with a chronicpost-infarct VSD. Primary transcatheter VSD closure in the acutesetting may also offer advantages over surgery. Methods and results: Between September 2003 and February 2008, 29 consecutive patientsunderwent primary transcatheter VSD closure. Clinical, procedural,and outcome data were collected. Patients were divided intothose with and those without cardiogenic shock at presentationfor risk stratification. The median follow-up time of survivingpatients was 730 days. The median time between VSD occurrenceand closure was 1 day [interquartile range (IQR) 1–3]and the initial procedural success rate was 86%. The shunt (Qp:Qs)could be reduced from 3.3 (IQR 2.3–3.8) to 1.4 (IQR 1.2–1.7;P < 0.001). Procedure-related complications such as majorresidual shunting, left ventricular rupture, and device embolizationoccurred in 41%. The overall 30-day survival rate was 35%. Mortalitywas higher for cardiogenic shock in comparison to non-shockpatients (88 vs. 38%, P < 0.001). Conclusion: Interventional acute VSD closure is a promising technique thatcan be performed with a high procedural success rate and mayoffer an alternative to surgery. Despite the less invasive technique,mortality of postinfarction VSD remains high, particularly inpatients with cardiogenic shock. Further developments in devicesand delivery techniques are required.     

Cardiac troponin I is increased after interventional closure of atrial septal defects.

This study was designed to assess possible myocardial injury caused by interventional closure of atrial septal defects (ASDs) compared to diagnostic catheterization by measuring cardiac troponin I (cTn-I). Forty patients were enrolled; in 33 ASDs were successfully closed, while in 7 a diagnostic balloon sizing of the defect was performed only. Total cTn-I increased significantly from 0.1 to 1.9 microg/l at the end of the intervention and 2.23 at 4 hr and decreased to 1.35 at 15 hr. No significant increase could be detected in patients with diagnostic balloon sizing only or of CK/CK-MB levels either. Following interventional closure of ASDs with Amplatzer septum/PFO occluders, increased cTn-I levels for several hours indicate some transient, reversible myocardial membrane instability due to the device. Discrimination of ventricular myocardial infarction might be possible by estimating less sensitive CK and CK-MB levels only.     

Transcatheter closure of perimembranous ventricular septal defects with Amplatzer occluder assessed by real-time three-dimensional echocardiography.

We report our initial experience in two patients using real-time three-dimensional echocardiography to assess perimembranous ventricular septal defect and device morphology and their relation with contiguous cardiac structure. Defect size and rims as well as device position and profile were displayed from the three-dimensional "en face" views. We think that real-time three-dimensional echocardiography could be a complementary approach to angiography and transesophageal echocardiography in performing transcatheter closure of perimembranous ventricular septal defect.     

A modified Cook sheath for closure of a large secundum atrial septal defect.

Transcatheter closure of large secundum atrial septal defects with deficient rims is difficult. Several techniques have been described to improve delivery of the occluder in anatomically challenging cases. Among these is a recently described technique using a modified delivery sheath with the creation of a bevel. However, the initial case report was complicated by malfunction and longitudinal splitting of the sheath. We describe the successful use of a modified delivery sheath for closure of a large atrial septal defect with a deficient rim.     

Perventricular device closure of isolated muscular ventricular septal defect in infants: A single centre experience

ObjectivesTo evaluate prospective single centre experience of mid-term safety and efficacy of perventricular device closure of isolated large muscular ventricular septal defect (mVSD) in high-risk infants.BackgroundSurgical closures of large mVSD in infants represent a challenge with significant morbidity.MethodsBetween August 2008–2010, perventricular closure was attempted in 24 infants of 6.01 ± 2.37 months age and 4.27 ± 0.56 kg weight under TEE guidance.ResultsThe device was successfully deployed in 21/24 infants. Size of mVSD was 8.42 ± 1.46 mm (6.1–12 mm). Mean procedure time was 28.8 ± 11.7 min. The closure rate was 84% immediately and 100% at 6 months. Four patients suffered major complications: 2-died, 1-esophageal perforation, 1-persistent CHB. At 26.23 ± 6.63 months follow-up two patients were symptomatic: 1-required device retrieval, 1-died of severe gastroenteritis.ConclusionPerventricular device closure of isolated mVSD appears feasible option at mid-term follow-up and may either substitute or complement the conventional surgical technique in selected cases depending on institutional paediatric cardiac surgery performance.